Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Alzamend Neuro, Inc. (ALZN) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/29/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Submission of Matters to...
08/16/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
08/07/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
04/26/2023 8-K Quarterly results
04/25/2023 8-K Quarterly results
04/03/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine to Treat Mild to Moderate Dementia of the Alzheimer’ s Type ATLANTA, GA, April 3, 2023 -- Alzamend Neuro, Inc. , an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’ s disease , bipolar disorder, major depressive disorder and post-traumatic stress disorder , today announced the initiation of a phase I/IIA clinical trial for its immunotherapy vaccine to treat mild to moderate dementia of the Alzheimer’ s type. The purpose of this trial is to assess the safety, tolerability, and efficacy of multiple ascending doses of ALZN002 compared with that of placebo in 20-30 subjects with mild to moderate morbidity. The primary goal of this clini..."
03/22/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Topline data expected in June 2023"
03/16/2023 8-K Quarterly results
Docs: "Alzamend Neuro, Inc. Condensed Balance Sheets January 31, 2023 April 30, 2022 ASSETS CURRENT ASSETS Cash $ 7,375,841 $ 14,063,811 Prepaid expenses and other current assets 546,303 349,723 Prepaid expenses - related party 494,668 - TOTAL CURRENT ASSETS 8,416,812 14,413,534 Property, plant and equipment, net 85,166 102,909 TOTAL ASSETS $ 8,501,978 $ 14,516,443 LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES Accounts payable and accrued liabilities $ 2,642,473 $ 1,162,850 Related party payable - 2,082 TOTAL CURRENT LIABILITIES 2,642,473 1,164,932 TOTAL LIABILITIES 2,642,473 1,164,932 COMMITMENTS AND CONTINGENCIES STOCKHOLDERS’ EQUITY Convertible Preferred stock, $0.0001 par value: 10,000,000 shares authorized; Series A Convertible Preferred Stock, $0.0001stated value per share, 1,360..."
02/03/2023 8-K Quarterly results
01/20/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Corporate Presentation"
11/16/2022 8-K Quarterly results
10/31/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine to Treat Mild to Moderate Dementia of the Alzheimer’ s Type ATLANTA, GA, October 31, 2022 -- Alzamend Neuro, Inc. , an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’ s disease , bipolar disorder, major depressive disorder and post-traumatic stress disorder , today announced receipt of a “Study May Proceed” letter from the U.S. Food and Drug Administration for a phase I/IIA clinical trial under its Investigational New Drug application for an immunotherapy to treat mild to moderate dementia of the Alzheimer’ s type. “We are grateful to receive this timely, favorable respons..."
10/05/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "About Alzamend Neuro Alzamend is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’ s, bipolar disorder, MDD and PTSD. Our mission is to rapidly develop and market safe and effective treatments. Our current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, salicylate, and L-proline, and ALZN002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’ s immunological system to combat Alzheimer’ s. Both of our product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-be..."
09/29/2022 8-K Quarterly results
09/22/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement"
08/15/2022 8-K Quarterly results
08/05/2022 8-K Quarterly results
07/18/2022 8-K Quarterly results
06/28/2022 8-K Quarterly results
06/06/2022 8-K Quarterly results
04/20/2022 8-K/A Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Corporate Presentation"
04/18/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Corporate Presentation"
12/17/2021 8-K Quarterly results
09/30/2021 8-K Quarterly results
08/17/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Alzamend Neuro Announces It Has Contracted With Altasciences to Conduct a Phase I Relative Bioavailability Study for AL001 for Dementia Related to Alzheimer’ s Disease in September 2021 TAMPA, FL., August 17, 2021—Alzamend Neuro, Inc. , an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced that it contracted Altasciences to conduct a six-month Phase I relative bioavailability study for AL001 for dementia related to Alzheimer’ s disease in September 2021. The Phase I first-in-human study is for the purpose of determining potential clinically safe and appropriate dosing for AL001 in future studies. AL001 is a lithium-delivering ionic cocrystal under development as an or..."
08/04/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer’ s Pursuant to the Securities Purchase Agreement with Digital Power Lending Tampa, FL, August 4, 2021 – Alzamend Neuro, Inc. announced that Digital Power Lending, LLC , a wholly owned subsidiary of Ault Global Holdings, Inc. , a diversified holding company, has made an additional investment in Alzamend, a related party of AGH and early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders. Additional Investment in Alzamend Neuro, Inc."
07/28/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase 1 Clinical Study Under its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer’ s Disease TAMPA, FL., July 28, 2021--Alzamend Neuro, Inc. , an early clinical-stage stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced receipt of U.S. Food and Drug Administration study may proceed letter for a Phase 1study under the Company’ s Investigational New Drug application for AL001, a lithium-based ionic cocrystal oral therapy for patients with dementia related to mild, moderate, and severe cognitive impairment associated with Alzheimer’ s disease. “We are grateful to receive this timely, favorable resp..."
07/23/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer’ s Disease AL002 is a Patented Method Using a Mutant-Peptide Sensitized Cell as a Cell-Based Therapeutic Vaccine TAMPA, FL, July 23, 2021 -- Alzamend Neuro, Inc. , a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced that it has received positive toxicology results for AL002 in a good laboratory practices toxicology study using a transgenic mouse model of Alzheimer’ s disease. The study was conducted by Charles River Laboratories. AL002 is a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore..."
06/22/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy